[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100438236":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":60,"collaborators":18,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":18,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":18,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":18,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients: ChromoSeq","EXPERIMENTAL","ChromoSeq will be performed on bone marrow DNA from consented patients in parallel with the standard of care cytogenetics, FISH, and the MyeloSeq gene panel obtained from that sample, in a CLIA licensed environment using CLIA-compliant ChromoSeq procedures.",[13],"Device: ChromoSeq",{"label":15,"type":16,"description":17,"interventionNames":18},"Stakeholders (Treating Physicians)","NO_INTERVENTION","-Stakeholders (treating physicians) will complete surveys\u002Fquestionnaires. As of protocol amendment 10\u002F31\u002F2023, the stakeholders (treating physicians) will no longer be completing surveys\u002Fquestionnaires.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DEVICE","ChromoSeq","Novel, streamlined whole genome sequencing approach",[9],[26],{"name":27,"affiliation":5,"role":28},"Meagan Jacoby, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},"CONTACT","314-747-8439","mjacoby@wustl.edu",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-90.19789,38.62727,{"lat":46,"lon":45},[49,50,51,54,56,58],{"name":27,"role":31,"phone":32,"phoneExt":18,"email":33},{"name":27,"role":28,"phone":18,"phoneExt":18,"email":18},{"name":52,"role":53,"phone":18,"phoneExt":18,"email":18},"Timothy Ley, M.D.","SUB_INVESTIGATOR",{"name":55,"role":53,"phone":18,"phoneExt":18,"email":18},"Mary Politi, Ph.D.",{"name":57,"role":53,"phone":18,"phoneExt":18,"email":18},"David Spencer, M.D., Ph.D.",{"name":59,"role":53,"phone":18,"phoneExt":18,"email":18},"Feng Gao, Ph.D.",{"type":61,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100438236","whole-genome-sequencing-chromoseq-as-an-adjunct-to-conventional-genomic-profiling-in-aml-and-mds-100438236",false,"NCT04986657","Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS","A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS","Inclusion Criteria Patient\n\n* Patient with a clinical suspicion for a new diagnosis of AML or MDS for whom the diagnostic molecular testing via the hematologic molecular algorithm (HMA) at BJH is requested or planned to be requested.\n* Adult patients 18 years or older.\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\n\nInclusion Criteria Physician\n\n* Treating physician at Washington University School of Medicine who directs therapy for individuals with hematologic malignancies.\n* Able and willing to complete standardized questionnaires about usability, and stakeholder perceptions of ChromoSeq during the ChromoSeq implementation process.\n\nExclusion Criteria Patient\n\n* Younger than 18 years of age\n\nExclusion Criteria Physician\n\n* Does not treat patients at Washington University School of Medicine",true,"ALL","18 Years",{"count":73,"type":74},325,"ESTIMATED","INTERVENTIONAL",[77],"NA","This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).",[80,81,82],"Whole Genome Sequencing","Acute Myeloid Leukemia","Myelodysplastic Syndromes","2025-10-14",{"date":85,"type":86},"2025-10-16","ACTUAL",{"date":88,"type":86},"2021-09-17",{"date":90,"type":74},"2027-12-31",{"name":5,"class":6},1]